Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 5/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18878391 | 0.87 | GRM4 (0.45) | GRM4NOTUMCFTRDYRK1BMTOR | |
| SCHEMBL14947692 | 0.84 | GRM4 (0.43) | GRM4NOTUMCFTRDYRK1BMTOR | |
| SCHEMBL20163069 | 0.84 | CFTR (0.43) | GRM4NOTUMCFTRDYRK1BMTOR | |
| SCHEMBL30036869 | 0.84 | CFTR (0.43) | GRM4NOTUMCFTRDYRK1BMTOR | |
| SCHEMBL20282465 | 0.82 | CFTR (0.44) | GRM4NOTUMCFTRDYRK1BMTOR | |
| SCHEMBL30036854 | 0.82 | CFTR (0.42) | CFTRRAB9A | |
| SCHEMBL20162673 | 0.82 | CFTR (0.42) | CFTRRAB9A | |
| SCHEMBL17040353 | 0.78 | RAB9A (0.44) | GRM4CFTRDYRK1BRAB9A | |
| SCHEMBL20162857 | 0.78 | CFTR (0.43) | GRM4NOTUMCFTRDYRK1BMTOR | |
| SCHEMBL30038218 | 0.78 | CFTR (0.43) | GRM4NOTUMCFTRDYRK1BMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| CN-110300589-B | Bicyclic heteroaryl derivatives as CFTR potentiators | 囊性纤维化基金会 | 2023-03-10 | — | — | CN | disclosed |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION | 2021-06-10 | — | — | US | disclosed |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | PFIZER INC. | 2020-01-16 | — | — | US | disclosed |
| US-20190330219-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | PFIZER INC. | 2019-10-31 | — | — | US | disclosed |
| US-10377762-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION | 2019-07-25 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| WO-2013071232-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TBL-1 BINDING TO DISEASE-ASSOCIATED MOLECULES | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377762-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RY2 | GRM4 2431/4885NOTUM 2987/4885CFTR 1/4885 |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RX3 | GRM4 2637/4885NOTUM 3382/4885CFTR 1/4885 |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | GRM4 3295/4885NOTUM 3642/4885CFTR 1/4885 |
| US-20190330219-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, SLC26A3, P2RY2 | GRM4 2431/4885NOTUM 2987/4885CFTR 1/4885 |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | GRM4 3295/4885NOTUM 3642/4885CFTR 1/4885 |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | GRM4 3295/4885NOTUM 3642/4885CFTR 1/4885 |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | GRM4 2223/4885NOTUM 3428/4885CFTR 1/4885 |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | GRM4 3295/4885NOTUM 3642/4885CFTR 1/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | GRM4 3750/4885NOTUM 3035/4885CFTR 1/4885 |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, P2RX1, P2RX5 | GRM4 3495/4885NOTUM 3686/4885CFTR 1/4885 |
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | TBL2, TBL3, TBL1XR1 | GRM4 3006/4885NOTUM 4724/4885CFTR 1401/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | GRM4 3495/4885NOTUM 3686/4885CFTR 1/4885 |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | GRM4 2223/4885NOTUM 3428/4885CFTR 1/4885 |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RY2 | GRM4 2431/4885NOTUM 2987/4885CFTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.